{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T02:24:28Z","timestamp":1775183068547,"version":"3.50.1"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jneuroim.2022.577904","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T11:43:26Z","timestamp":1654170206000},"page":"577904","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Distinguishing CNS neurosarcoidosis from multiple sclerosis and an approach to \u201coverlap\u201d cases"],"prefix":"10.1016","volume":"369","author":[{"given":"Fiona","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Sean","family":"Riminton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudarshini","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen W.","family":"Reddel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd A.","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2022.577904_bb0005","first-page":"95","article-title":"A review of angiotensin converting enzyme in health and disease","volume":"8","author":"Allen","year":"1991","journal-title":"Sarcoidosis"},{"issue":"7","key":"10.1016\/j.jneuroim.2022.577904_bb0010","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1007\/s00415-021-10421-z","article-title":"Effects of immunotherapies and clinical outcomes in neurosarcoidosis: a retrospective cohort study","volume":"268","author":"Arun","year":"2021","journal-title":"J. Neurol."},{"issue":"24","key":"10.1016\/j.jneuroim.2022.577904_bb0015","doi-asserted-by":"crossref","first-page":"e2545","DOI":"10.1212\/WNL.0000000000009491","article-title":"Distinguishing neurosarcoidosis from multiple sclerosis based on CSF analysis: a retrospective study","volume":"94","author":"Arun","year":"2020","journal-title":"Neurology."},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2022.577904_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2009.09.002","article-title":"Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis","volume":"219","author":"Awad","year":"2010","journal-title":"J. Neuroimmunol."},{"issue":"4","key":"10.1016\/j.jneuroim.2022.577904_bb0025","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/ana.20016","article-title":"Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion","volume":"55","author":"Barnett","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577904_bb0030","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.cnp.2019.03.002","article-title":"The electrophysiological assessment of visual function in multiple sclerosis","volume":"4","author":"Barton","year":"2019","journal-title":"Clin. Neurophysiol. Pract."},{"issue":"2","key":"10.1016\/j.jneuroim.2022.577904_bb0035","first-page":"113","article-title":"Calcium and vitamin D metabolism in sarcoidosis","volume":"30","author":"Baughman","year":"2013","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.jneuroim.2022.577904_bb0040","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.clineuro.2015.05.032","article-title":"The use of cladribine in neurosarcoidosis: a report of two cases","volume":"136","author":"Bhagwan","year":"2015","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"6578","key":"10.1016\/j.jneuroim.2022.577904_bb0045","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jneuroim.2022.577904_bb0050","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0002-9394(14)74235-7","article-title":"International uveitis study group recommendations for the evaluation of intraocular inflammatory disease","volume":"103","author":"Bloch-Michel","year":"1987","journal-title":"Am J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.jneuroim.2022.577904_bb0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1600-0404.2004.00278.x","article-title":"Internuclear ophthalmoplegia: causes and long-term follow-up in 65 patients","volume":"110","author":"Bola\u00f1os","year":"2004","journal-title":"Acta Neurol. Scand."},{"issue":"6","key":"10.1016\/j.jneuroim.2022.577904_bb0060","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1212\/WNL.0b013e3181ec7ff9","article-title":"A case of neurosarcoidosis successfully treated with rituximab","volume":"75","author":"Bomprezzi","year":"2010","journal-title":"Neurology."},{"issue":"2","key":"10.1016\/j.jneuroim.2022.577904_bb0065","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1212\/WNL.62.2.226","article-title":"Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination","volume":"62","author":"Bot","year":"2004","journal-title":"Neurology."},{"issue":"285","key":"10.1016\/j.jneuroim.2022.577904_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2015.05.020","article-title":"Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of neurosarcoidosis","author":"Bridel","year":"2015","journal-title":"J. Neuroimmunol."},{"issue":"10076","key":"10.1016\/j.jneuroim.2022.577904_bb0075","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/S0140-6736(16)30959-X","article-title":"Diagnosis of multiple sclerosis: progress and challenges","volume":"389","author":"Brownlee","year":"2017","journal-title":"Lancet."},{"issue":"3","key":"10.1016\/j.jneuroim.2022.577904_bb0080","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1600-0404.2010.01388.x","article-title":"Bilateral and recurrent optic neuritis in multiple sclerosis","volume":"123","author":"Burman","year":"2011","journal-title":"Acta Neurol. Scand."},{"issue":"24","key":"10.1016\/j.jneuroim.2022.577904_bb9128","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1212\/WNL.0000000000004740","article-title":"Epilepsy in multiple sclerosis: A nationwide population-based register study","volume":"89","author":"Burman","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jneuroim.2022.577904_bb0085","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/jnnp.2008.144972","article-title":"Azathioprine for multiple sclerosis","volume":"80","author":"Casetta","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"7","key":"10.1016\/j.jneuroim.2022.577904_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066308","article-title":"Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review","volume":"8","author":"Castillo-Trivino","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jneuroim.2022.577904_bb0095","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.semarthrit.2012.03.008","article-title":"Sarcoidosis triggered by interferon-Beta treatment of multiple sclerosis: a case report and focused literature review","volume":"42","author":"Chakravarty","year":"2012","journal-title":"Semin. Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.jneuroim.2022.577904_bb0100","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/RLU.0000000000001516","article-title":"Neurosarcoidosis on FET and FDG PET\/CT","volume":"42","author":"Chan","year":"2017","journal-title":"Clin. Nucl. Med."},{"issue":"4","key":"10.1016\/j.jneuroim.2022.577904_bb0105","first-page":"655","article-title":"MR of CNS sarcoidosis: correlation of imaging features to clinical symptoms and response to treatment","volume":"20","author":"Christoforidis","year":"1999","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"1","key":"10.1016\/j.jneuroim.2022.577904_bb0110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12948-015-0025-9","article-title":"Rituximab in refractory sarcoidosis: a single centre experience","volume":"13","author":"Cinetto","year":"2015","journal-title":"Clin. Mol. Allergy"},{"issue":"2","key":"10.1016\/j.jneuroim.2022.577904_bb0115","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.sjopt.2017.12.003","article-title":"Uveitis and internuclear ophthalmoplegia as ocular manifestations of sarcoidosis","volume":"32","author":"Cirone","year":"2018","journal-title":"Saudi J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.jneuroim.2022.577904_bb0120","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00415-017-8444-9","article-title":"Long-term outcomes of refractory neurosarcoidosis treated with infliximab","volume":"264","author":"Cohen Aubart","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577904_bb0125","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jneuroim.2022.577904_bb0130","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1212\/01.WNL.0000046587.83503.1E","article-title":"MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals","volume":"60","author":"Cotton","year":"2003","journal-title":"Neurology."},{"issue":"5","key":"10.1016\/j.jneuroim.2022.577904_bb0135","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/MCP.0b013e3283642a7a","article-title":"Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide","volume":"19","author":"Cremers","year":"2013","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"3","key":"10.1016\/j.jneuroim.2022.577904_bb0140","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1191\/1352458505ms1186oa","article-title":"Trigeminal involvement in multiple sclerosis: magnetic resonance imaging findings with clinical correlation in a series of patients","volume":"11","author":"da Silva","year":"2005","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2022.577904_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101456","article-title":"Clinical and radiological findings of facial paralysis in multiple sclerosis","volume":"37","author":"Di Stadio","year":"2020","journal-title":"Mult. Scler Relat. Disord."},{"key":"10.1016\/j.jneuroim.2022.577904_bb0150","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1212\/WNL.57.5.927","article-title":"Long-term follow-up of neurosarcoidosis","volume":"57","author":"Ferriby","year":"2001","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jneuroim.2022.577904_bb0155","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1474-4422(15)00393-2","article-title":"MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines","volume":"15","author":"Filippi","year":"2016","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.jneuroim.2022.577904_bb0160","article-title":"Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis","author":"Filippini","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jneuroim.2022.577904_bb0165","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/B978-0-444-63432-0.00019-0","article-title":"Autoimmune myelopathies","volume":"133","author":"Flanagan","year":"2016","journal-title":"Handb. Clin. Neurol."},{"issue":"11","key":"10.1016\/j.jneuroim.2022.577904_bb0170","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.mayocp.2013.07.019","article-title":"[(18)F]-fluorodeoxyglucose-positron emission tomography in patients with active myelopathy","volume":"88","author":"Flanagan","year":"2013","journal-title":"Mayo Clin. Proc."},{"issue":"2","key":"10.1016\/j.jneuroim.2022.577904_bb0175","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.24881","article-title":"Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients","volume":"81","author":"Flanagan","year":"2017","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2022.577904_bb0180","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12883-016-0741-x","article-title":"Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis","volume":"16","author":"Fritz","year":"2016","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jneuroim.2022.577904_bb0185","first-page":"3642735","article-title":"Two cases of Heerfordt\u2019s syndrome: a rare manifestation of sarcoidosis","volume":"2016","author":"Fujiwara","year":"2016","journal-title":"Case Rep. Otolaryngol."},{"issue":"4","key":"10.1016\/j.jneuroim.2022.577904_bb0190","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/ced.12793","article-title":"Sarcoidosis following successful treatment of pemphigus vulgaris with rituximab: a rituximab-induced reaction further supporting B-cell contribution to sarcoidosis pathogenesis?","volume":"41","author":"Galimberti","year":"2016","journal-title":"Clin. Exp. Dermatol."},{"issue":"20","key":"10.1016\/j.jneuroim.2022.577904_bb0195","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1212\/WNL.0000000000004644","article-title":"Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series","volume":"89","author":"Gelfand","year":"2017","journal-title":"Neurology."},{"issue":"2","key":"10.1016\/j.jneuroim.2022.577904_bb0200","first-page":"159","article-title":"Significance of multimodality evoked potential abnormalities in sarcoidosis","volume":"14","author":"Gott","year":"1997","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"13","key":"10.1016\/j.jneuroim.2022.577904_bb0205","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1177\/1352458518771276","article-title":"Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment","volume":"24","author":"Graf","year":"2018","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.jneuroim.2022.577904_bb0210","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41572-019-0107-y","article-title":"Publisher correction: sarcoidosis","volume":"5","author":"Grunewald","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"1","key":"10.1016\/j.jneuroim.2022.577904_bb0215","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0733-8619(03)00054-9","article-title":"Neurologic manifestations of sarcoidosis","volume":"20","author":"Gullapalli","year":"2002","journal-title":"Neurol. Clin."},{"issue":"3","key":"10.1016\/j.jneuroim.2022.577904_bb0220","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/WCO.0000000000000683","article-title":"Pseudotumoral demyelinating lesions: diagnostic approach and long-term outcome","volume":"32","author":"Hardy","year":"2019","journal-title":"Curr. Opin. Neurol."},{"issue":"9","key":"10.1016\/j.jneuroim.2022.577904_bb0225","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1474-4422(16)30043-6","article-title":"Atypical inflammatory demyelinating syndromes of the CNS","volume":"15","author":"Hardy","year":"2016","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.jneuroim.2022.577904_bb0230","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"OPERA I and OPERA II clinical investigators. Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"341","key":"10.1016\/j.jneuroim.2022.577904_bb0235","article-title":"Leukocyte profiles in blood and CSF distinguish neurosarcoidosis from multiple sclerosis","author":"Heming","year":"2020","journal-title":"J. Neuroimmunol."},{"issue":"8","key":"10.1016\/j.jneuroim.2022.577904_bb0240","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/jnnp-2020-325665","article-title":"Under the aegis of the French Multiple Sclerosis Society. TNF-\u03b1 inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosis","volume":"92","author":"Hilezian","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9","key":"10.1016\/j.jneuroim.2022.577904_bb0245","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1177\/0333102413485658","article-title":"The international classification of headache disorders, 3rd edition (beta version)","volume":"33","author":"ICHD-3","year":"2013","journal-title":"Cephalalgia"},{"issue":"7","key":"10.1016\/j.jneuroim.2022.577904_bb0250","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/17512433.2018.1486706","article-title":"Treatment of sarcoidosis: grading the evidence","volume":"11","author":"James","year":"2018","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.jneuroim.2022.577904_bb0255","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/jnnp.2007.124263","article-title":"Sarcoidosis of the nervous system","volume":"7","author":"Joseph","year":"2007","journal-title":"Pract. Neurol."},{"issue":"2","key":"10.1016\/j.jneuroim.2022.577904_bb0260","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/1352458508097923","article-title":"Angiotensin-converting enzyme (ACE) and ACE2 levels in the cerebrospinal fluid of patients with multiple sclerosis","volume":"15","author":"Kawajiri","year":"2009","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/j.jneuroim.2022.577904_bb0265","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1007\/s00415-018-8928-2","article-title":"Sarcoidosis of the central nervous system: clinical features, imaging, and CSF results","volume":"265","author":"Kidd","year":"2018","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.jneuroim.2022.577904_bb0270","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000270","article-title":"Optic neuropathy associated with systemic sarcoidosis","volume":"3","author":"Kidd","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.jneuroim.2022.577904_bb0275","first-page":"209","article-title":"Role of pulmonary evaluation in diagnosis of Neurosarcoidosis","volume":"33","author":"Kingah","year":"2016","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"11","key":"10.1016\/j.jneuroim.2022.577904_bb0280","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1001\/archneurol.2010.271","article-title":"Spinal cord ring enhancement in multiple sclerosis","volume":"67","author":"Klawiter","year":"2010","journal-title":"Arch. Neurol."},{"issue":"9","key":"10.1016\/j.jneuroim.2022.577904_bb0285","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1212\/WNL.0000000000008015","article-title":"The spectrum of immune-mediated and inflammatory lesions of the brainstem: clues to diagnosis","volume":"93","author":"Law","year":"2019","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2022.577904_bb0290","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled Mul- ticenter study. The Lenercept multiple sclerosis study group and the University of British Columbia MS\/MRI analysis group","volume":"53","author":"Lenercept Multiple Sclerosis Study Group","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2022.577904_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinbiochem.2018.06.010","article-title":"Focus on increased serum angiotensin-converting enzyme level: from granulomatous diseases to genetic mutations","volume":"59","author":"Lopez-Sublet","year":"2018","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.jneuroim.2022.577904_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102526","article-title":"Anemia and sarcoidosis following treatment with alemtuzumab","volume":"46","author":"Love","year":"2020","journal-title":"Mult. Scler Relat. Disord."},{"issue":"5","key":"10.1016\/j.jneuroim.2022.577904_bb0305","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.msard.2015.06.012","article-title":"Neurosarcoidosis as an MS mimic: the trials and tribulations of making a diagnosis","volume":"4","author":"MacLean","year":"2015","journal-title":"Mult. Scler Relat. Disord."},{"issue":"2","key":"10.1016\/j.jneuroim.2022.577904_bb0310","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.radcr.2020.11.047","article-title":"Acute central nervous system vasculitis as a manifestation of neurosarcoidosis: a case report and literature review","volume":"16","author":"Maekawa","year":"2020","journal-title":"Radiol. Case Rep."},{"issue":"2","key":"10.1016\/j.jneuroim.2022.577904_bb0315","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ana.25146","article-title":"Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies","volume":"83","author":"Maggi","year":"2018","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.jneuroim.2022.577904_bb0320","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/ana.22230","article-title":"A gradient of neuronal loss and meningeal inflammation in multiple sclerosis","volume":"68","author":"Magliozzi","year":"2010","journal-title":"Ann. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.jneuroim.2022.577904_bb0325","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jns.2015.05.013","article-title":"Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis","volume":"355","author":"Mealy","year":"2015","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.jneuroim.2022.577904_bb0330","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1080\/09273940802687812","article-title":"Ocular features in neurosarcoidosis","volume":"17","author":"Menezo","year":"2009","journal-title":"Ocul. Immunol. Inflamm."},{"issue":"3","key":"10.1016\/j.jneuroim.2022.577904_bb0335","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1212\/WNL.38.3.378","article-title":"Magnetic resonance imaging in central nervous system sarcoidosis","volume":"38","author":"Miller","year":"1988","journal-title":"Neurology."},{"issue":"12","key":"10.1016\/j.jneuroim.2022.577904_bb0340","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jneuroim.2022.577904_bb0345","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-5945-2-15","article-title":"Successful treatment of recalcitrant cutaneous sarcoidosis with fumaric acid esters","volume":"2","author":"Nowack","year":"2002","journal-title":"BMC Dermatol."},{"issue":"5","key":"10.1016\/j.jneuroim.2022.577904_bb0350","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s004150170175","article-title":"Neurosarcoidosis: a review of its intracranial manifestation","volume":"248","author":"Nowak","year":"2001","journal-title":"J. Neurol."},{"issue":"6 Pt 2","key":"10.1016\/j.jneuroim.2022.577904_bb0355","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1016\/j.lpm.2011.12.017","article-title":"Neurosarcoidosis: clinical manifestations, diagnosis and treatment","volume":"41","author":"Nozaki","year":"2012","journal-title":"Presse Med."},{"key":"10.1016\/j.jneuroim.2022.577904_bb0360","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1600-0404.1986.tb04623.x","article-title":"Visual and auditory evoked potentials in the early diagnosis and follow-up of neurosarcoidosis","volume":"74","author":"Oksanen","year":"1986","journal-title":"Acta Neurol. Scand."},{"issue":"11","key":"10.1016\/j.jneuroim.2022.577904_bb0365","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S1474-4422(06)70581-6","article-title":"Sex ratio of multiple sclerosis in Canada: a longitudinal study","volume":"5","author":"Orton","year":"2006","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/j.jneuroim.2022.577904_bb0370","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nrg3502","article-title":"Genetic insights into common pathways and complex relationships among immune-mediated diseases","volume":"14","author":"Parkes","year":"2013","journal-title":"Nat. Rev. Genet."},{"issue":"7","key":"10.1016\/j.jneuroim.2022.577904_bb0375","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/qjmed\/hcp042","article-title":"Presentations and outcomes of neurosarcoidosis: a study of 54 cases","volume":"102","author":"Pawate","year":"2009","journal-title":"QJM."},{"key":"10.1016\/j.jneuroim.2022.577904_bb0380","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s00415-010-5623-3","article-title":"Soluble CSF interleukin 2 receptor as indicator of neuro- sarcoidosis","volume":"257","author":"Petereit","year":"2010","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2022.577904_bb0385","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1017\/S0317167100042773","article-title":"A comparison of visual, brainstem auditory, and somatosensory evoked potentials in multiple sclerosis","volume":"8","author":"Purves","year":"1981","journal-title":"Can. J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.jneuroim.2022.577904_bb0390","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1468-1331.2008.02406.x","article-title":"Prevalence of migraine, tension-type headache and trigeminal neuralgia in multiple sclerosis","volume":"16","author":"Putzki","year":"2009","journal-title":"Eur. J. Neurol."},{"issue":"1003","key":"10.1016\/j.jneuroim.2022.577904_bb0395","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/pgmj.2008.067769","article-title":"Immune-mediated and chronic inflammatory disease in people with sarcoidosis: disease associations in a large UK database","volume":"85","author":"Rajoriya","year":"2009","journal-title":"Postgrad. Med. J."},{"issue":"3","key":"10.1016\/j.jneuroim.2022.577904_bb0400","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120829","article-title":"A predictive model for corticosteroid response in individual patients with MS relapses","volume":"10","author":"Rakusa","year":"2015","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jneuroim.2022.577904_bb0405","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/ene.13932","article-title":"Uveitis and optic perineuritis in the context of myelin oligodendrocyte glycoprotein antibody seropositivity","volume":"26","author":"Ramanathan","year":"2019","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.jneuroim.2022.577904_bb0410","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/archneur.1992.00530270069020","article-title":"Acute radicular pain as a presenting symptom in multiple sclerosis","volume":"49","author":"Ramirez-Lassepas","year":"1992","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2022.577904_bb0415","doi-asserted-by":"crossref","first-page":"13735","DOI":"10.1038\/s41598-021-92967-6","article-title":"Clinical characterization and outcomes of 85 patients with neurosarcoidosis","volume":"11","author":"Ramos-Casals","year":"2021","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.jneuroim.2022.577904_bb0420","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/cpt.1304","article-title":"Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update","volume":"105","author":"Relling","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.jneuroim.2022.577904_bb0425","doi-asserted-by":"crossref","first-page":"e924","DOI":"10.1212\/NXI.0000000000000924","article-title":"Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders","volume":"8","author":"Rinaldi","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"7","key":"10.1016\/j.jneuroim.2022.577904_bb0430","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/1752-1947-7-270","article-title":"Cutaneous and pulmonary sarcoidosis following treatment of multiple sclerosis with interferon-\u03b2-1b: a case report","author":"Sahraian","year":"2013","journal-title":"J. Med. Case Rep."},{"issue":"12","key":"10.1016\/j.jneuroim.2022.577904_bb0435","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s00415-011-6080-3","article-title":"Clinical features of spinal cord sarcoidosis: analysis of 17 neurosarcoidosis patients","volume":"258","author":"Sakushima","year":"2011","journal-title":"J. Neurol."},{"issue":"9","key":"10.1016\/j.jneuroim.2022.577904_bb0440","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/14737175.2021.1971077","article-title":"Tumefactive demyelination: updated perspectives on diagnosis and management","volume":"21","author":"S\u00e1nchez","year":"2021","journal-title":"Expert. Rev. Neurother."},{"issue":"3","key":"10.1016\/j.jneuroim.2022.577904_bb0445","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/jnnp.2008.149989","article-title":"Treatment of refractory neurosarcoidosis with infliximab","volume":"81","author":"Santos","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"20","key":"10.1016\/j.jneuroim.2022.577904_bb0450","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/BF01717829","article-title":"Angiotensin I converting enzyme in cerebrospinal fluid of patients with neurological diseases","volume":"65","author":"Schweisfurth","year":"1987","journal-title":"Klin. Wochenschr."},{"key":"10.1016\/j.jneuroim.2022.577904_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117621","article-title":"Neurosarcoidosis mimicry of MS: clues from cases with CNS tissue diagnosis","volume":"429","author":"Scott","year":"2021","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.jneuroim.2022.577904_bb0460","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/NRL.0b013e3181b287df","article-title":"Neurosarcoidosis mimicry of multiple sclerosis: clinical, laboratory, and imaging characteristics","volume":"16","author":"Scott","year":"2010","journal-title":"Neurologist."},{"issue":"4","key":"10.1016\/j.jneuroim.2022.577904_bb0465","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3390\/cells10040766","article-title":"Sarcoidosis: a clinical overview from symptoms to diagnosis","volume":"10","author":"S\u00e8ve","year":"2021","journal-title":"Cells."},{"issue":"5","key":"10.1016\/j.jneuroim.2022.577904_bb0470","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3174\/ajnr.A1470","article-title":"Correlation of MR imaging findings and clinical manifestations in neurosarcoidosis","volume":"30","author":"Shah","year":"2009","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"2","key":"10.1016\/j.jneuroim.2022.577904_bb0475","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2214\/ajr.182.2.1820289","article-title":"Imaging manifestations of neurosarcoidosis","volume":"182","author":"Smith","year":"2004","journal-title":"AJR Am. J. Roentgenol."},{"issue":"5","key":"10.1016\/j.jneuroim.2022.577904_bb0480","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1399-0004.2008.00970.x","article-title":"Advances in the genetics of sarcoidosis","volume":"73","author":"Smith","year":"2008","journal-title":"Clin. Genet."},{"issue":"1","key":"10.1016\/j.jneuroim.2022.577904_bb0485","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1046\/j.1528-1157.2001.48699.x","article-title":"Seizures in multiple sclerosis","volume":"42","author":"Sokic","year":"2001","journal-title":"Epilepsia."},{"issue":"9","key":"10.1016\/j.jneuroim.2022.577904_bb0490","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1001\/archneur.1985.04060080095022","article-title":"Sarcoidosis and its neurological manifestations","volume":"42","author":"Stern","year":"1985","journal-title":"Arch. Neurol."},{"issue":"12","key":"10.1016\/j.jneuroim.2022.577904_bb0495","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/jamaneurol.2018.2295","article-title":"Definition and consensus diagnostic criteria for Neurosarcoidosis: from the Neurosarcoidosis consortium consensus group","volume":"75","author":"Stern","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2022.577904_bb0500","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1212\/WNL.31.12.1545","article-title":"Visual evoked potentials in sarcoidosis","volume":"31","author":"Streletz","year":"1981","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jneuroim.2022.577904_bb0505","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1177\/1352458519840747","article-title":"Relapsing lumbosacral myeloradiculitis: an unusual presentation of MOG antibody disease","volume":"26","author":"Sundaram","year":"2020","journal-title":"Mult. Scler. J."},{"issue":"5","key":"10.1016\/j.jneuroim.2022.577904_bb0510","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1183\/09031936.00224513","article-title":"Rituximab in the treatment of refractory pulmonary sarcoidosis","volume":"43","author":"Sweiss","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jneuroim.2022.577904_bb0515","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1212\/WNL.0b013e3182703ff7","article-title":"Two cases of lumbosacral myeloradiculitis with anti-aquaporin-4 antibody","volume":"79","author":"Takai","year":"2012","journal-title":"Neurology."},{"issue":"7","key":"10.1016\/j.jneuroim.2022.577904_bb0520","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3109\/07853890.2015.1093164","article-title":"Challenges in the diagnosis and treatment of neurosarcoidosis","volume":"47","author":"Tana","year":"2015","journal-title":"Ann. Med."},{"issue":"1","key":"10.1016\/j.jneuroim.2022.577904_bb0525","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/cells11010059","article-title":"Clinical features, histopathology and differential diagnosis of sarcoidosis","volume":"11","author":"Tana","year":"2021","journal-title":"Cells."},{"issue":"5","key":"10.1016\/j.jneuroim.2022.577904_bb0530","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1210\/er.2016-1070","article-title":"Vitamin D-mediated hypercalcemia: mechanisms, diagnosis, and treatment","volume":"37","author":"Tebben","year":"2016","journal-title":"Endocr. Rev."},{"issue":"5","key":"10.1016\/j.jneuroim.2022.577904_bb0535","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1136\/jnnp.63.5.682","article-title":"Isolated cranial nerve palsies in multiple sclerosis","volume":"63","author":"Th\u00f6mke","year":"1997","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.jneuroim.2022.577904_bb0540","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"17","key":"10.1016\/j.jneuroim.2022.577904_bb0545","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1056\/NEJMc032345","article-title":"Treatment of refractory neurosarcoidosis with cladribine","volume":"350","author":"Tikoo","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jneuroim.2022.577904_bb0550","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/1756285613478870","article-title":"Neuroradiological evaluation of demyelinating disease","volume":"6","author":"Tillema","year":"2013","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"1","key":"10.1016\/j.jneuroim.2022.577904_bb0555","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1445-5994.2011.02612.x","article-title":"New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication","volume":"42","author":"Tong","year":"2012","journal-title":"Intern. Med. J."},{"issue":"1","key":"10.1016\/j.jneuroim.2022.577904_bb0560","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(13)70259-X","article-title":"Optic neuritis","volume":"13","author":"Toosy","year":"2014","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jneuroim.2022.577904_bb0565","article-title":"Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis \u2013 a cohort study","volume":"7","author":"Torgauten","year":"2021","journal-title":"Mult. Scler J. Exp. Transl. Clin."},{"issue":"Suppl. 3","key":"10.1016\/j.jneuroim.2022.577904_bb0570","first-page":"iii11","article-title":"Imaging in multiple sclerosis","volume":"76","author":"Trip","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"8","key":"10.1016\/j.jneuroim.2022.577904_bb0575","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1136\/jnnp-2018-319002","article-title":"Immune-mediated conditions affecting the brain, eye and ear (BEE syndromes)","volume":"90","author":"Triplett","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.jneuroim.2022.577904_bb0580","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1212\/CPJ.0000000000000629","article-title":"Multiple sclerosis and sarcoidosis: a case for coexistence","volume":"9","author":"Tyshkov","year":"2019","journal-title":"Neurol. Clin Pract."},{"issue":"2","key":"10.1016\/j.jneuroim.2022.577904_bb0585","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ncl.2010.12.007","article-title":"Individual and joint action of environmental factors and risk of MS","volume":"29","author":"van der Mei","year":"2011","journal-title":"Neurol. Clin."},{"issue":"3","key":"10.1016\/j.jneuroim.2022.577904_bb0590","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","article-title":"Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Wallin","year":"2019","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.jneuroim.2022.577904_bb0595","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1136\/jnnp.45.6.494","article-title":"Evoked potential changes in clinically definite multiple sclerosis: a two year follow up study","volume":"45","author":"Walsh","year":"1982","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"8","key":"10.1016\/j.jneuroim.2022.577904_bb0600","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","article-title":"2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis","volume":"20","author":"Wattjes","year":"2021","journal-title":"Lancet Neurol."},{"issue":"14","key":"10.1016\/j.jneuroim.2022.577904_bb0605","article-title":"Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)","author":"Wiendl","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"13","key":"10.1016\/j.jneuroim.2022.577904_bb0610","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1177\/1352458518790391","article-title":"Sarcoidosis following alemtuzumab treatment for multiple sclerosis","volume":"24","author":"Willis","year":"2018","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.jneuroim.2022.577904_bb0615","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.clineuro.2008.02.009","article-title":"Isolated cranial nerve palsies in multiple sclerosis","volume":"110","author":"Zadro","year":"2008","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"2","key":"10.1016\/j.jneuroim.2022.577904_bb0620","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/qjmed\/92.2.103","article-title":"Central nervous system sarcoidosis\u2013diagnosis and management","volume":"92","author":"Zajicek","year":"1999","journal-title":"QJM"},{"issue":"7","key":"10.1016\/j.jneuroim.2022.577904_bb0625","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1212\/WNL.0000000000002992","article-title":"Central canal enhancement and the trident sign in spinal cord sarcoidosis","volume":"87","author":"Zalewski","year":"2016","journal-title":"Neurology."},{"issue":"2","key":"10.1016\/j.jneuroim.2022.577904_bb0630","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/09273940490895344","article-title":"Multiple sclerosis-associated uveitis","volume":"12","author":"Zein","year":"2004","journal-title":"Ocul. Immunol. Inflamm."},{"issue":"11","key":"10.1016\/j.jneuroim.2022.577904_bb0635","article-title":"Successful therapy with rituximab in three patients with probable neurosarcoidosis","author":"Zella","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"3","key":"10.1016\/j.jneuroim.2022.577904_bb0640","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000358428","article-title":"Multi-organ sarcoidosis treatment with fumaric acid esters: a case report and review of the literature","volume":"228","author":"Zouboulis","year":"2014","journal-title":"Dermatology."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572822000996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572822000996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:41:25Z","timestamp":1759048885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572822000996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":129,"alternative-id":["S0165572822000996"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2022.577904","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinguishing CNS neurosarcoidosis from multiple sclerosis and an approach to \u201coverlap\u201d cases","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2022.577904","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"577904"}}